T. D. Glebovskaya

T. D. Glebovskaya

Auto-generated profile, based on publicly available information

T. D. Glebovskaya

Almazov National Medical Research Centre

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2025 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MSM. A. Simakova
M. A. Simakova
SPS. I. Parkhomenko
S. I. Parkhomenko
KLK. B. Lapshin
K. B. Lapshin
TGT. D. Glebovskay
T. D. Glebovskay
DKD. V. Karpova
D. V. Karpova
OMOlga Moiseeva
Olga Moiseeva
Aim. Comparison of conservative and invasive treatment strategies in patients with intermediate-high risk pulmonary embolism (PE) based on a multimodal assessment of efficacy and safety.Material and methods. This single-center, open-label, randomized, comparative trial will include 100 patients with a verified diagnosis of PE with intermediate-high risk of 30-day mortality. Patients will be randomized 1:1 to standard anticoagulant therapy or selective low-dose alteplase transcatheter thrombolysis. Patients will be followed for 12 months. The primary endpoint is a decrease in the right ventricle to left ventricle ratio by 20% or more from baseline at 48±6 hours after initiation of therapy. There are secondary endpoints: patient hemodynamic instability; ISTH major bleeding; Qanadli index decrease at 48 hours; degree of residual thrombosis with reduced perfusion at 3-6 months; incidence of post-thromboembolic syndrome at 3-6 months; 30-day, 90-day, and 1-year mortality.Conclusion. The study will provide important clinical data on the short- and long-term efficacy and safety of different treatment approaches in patients with intermediate-to-high-risk acute pulmonary embolism.

13 March 2023 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
SPS. I. Parkhomenko
S. I. Parkhomenko
KLK. B. Lapshin
K. B. Lapshin
TGT. D. Glebovskaya
T. D. Glebovskaya
KMK. N. Malikov
K. N. Malikov
NMN. V. Marukyan
N. V. Marukyan
MSM. A. Simakova
M. A. Simakova
Selective transcatheter thrombolysis (STT) in patients with pulmonary embolism (PE) with an intermediatehigh risk of 30-day mortality is an option for rapid lung reperfusion with a decrease in right ventricular (RV) afterload, which largely determines the prognosis of patients.Objective. Comparison of the efficacy of STT using reduced doses of alteplase and routine conservative treatment of patients with PE with an intermediate-high risk of 30-day mortality using a retrospective analysis of the data from Almazov National Medical Research Centre.Design and methods. The retrospective single-center study included 45 patients (18 men (40 %) and 27 women (60 %)) admitted to the anaesthesiology and resuscitation department of the Almazov National Medical Research Centre from January 1, 2021 to May 1, 2022 with the confirmed diagnosis of acute PE. Intermediate-high risk patients (22 people (57,9 %)) were divided into two groups according to the treatment strategy: the group receiving standard anticoagulant therapy (n = 15 (68,2 %)) and the group with STT by alteplase at a total dose of 50 mg (n = 7 (31,8 %)). In order to assess the effectiveness of treatment, the main laboratory and instrumental indicators were compared based on data from the medical information system.Results. Baseline clinical characteristics of the compared groups did not differ. Systolic pressure in the pulmonary artery (SPPA) in the transcatheter treatment group decreased from 59 [50; 82] to 35 [30; 65] mmHg; in the conservative treatment group: from 65 [50; 70] to 52 [40; 59] mmHg. In the selective thrombolysis group, there was a significant trend for a greater decrease SPPA compared to the anticoagulant therapy group: –25 [–29; –3] versus — 10 [–23; –6] mmHg, р = 0,047. There was a significant change in the level of leukocytes and platelets in the group of transcatheter treatment versus anticoagulant therapy: –5,0 [6,1; 4,1] × 109/l vs –2,8 [4,3; 1,8] × 109/l (p = 0,017) and 130 [32; 181] × 1012/l vs 31 [2; 56] × 1012/l (р = 0,044). There were no significant differences in the change in the RV size between the groups. The groups did not differ in the total number of hemorrhagic complications. When bleeding was divided by severity (according to the TIMI classification), moderate bleeding was more common in the selective thrombolysis group (2 cases versus 0 with a conservative approach, p = 0,014). There were no differences in the duration of treatment in the anaesthesiology and resuscitation department and the terms of inpatient treatment.Conclusions. A single center retrospective study demonstrated the high quality of approaches to the diagnosis and treatment of PE in terms of current guidelines. The STT with reduced doses of alteplase was associated with a more significant decrease SPPA and normalization of hemogram parameters when compared to the standard treatment approach. At the same time, selective thrombolysis was associated with a higher risk of hemorrhagic complications. A prospective study of the efficacy and safety of prolonged STT with the selection of the dose of thrombolytic in patients with PE with an intermediate-high risk of 30-day mortality is needed.

4 June 2026 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
MSM. A. Simakova
M. A. Simakova
SPS. I. Parkhomenko
S. I. Parkhomenko
KLK. B. Lapshin
K. B. Lapshin
TGT. D. Glebovskaya
T. D. Glebovskaya
VKV. S. Krasnov
V. S. Krasnov
OMOlga Moiseeva
Olga Moiseeva
Aim. To compare the efficacy and safety of ultrasound-assisted catheter-directed thrombolysis (UACDT) using EkoSonic technology (EKOS Corporation, Bothell, Washington, USA) and a routine conservative approach with anticoagulant therapy (ACT) in patients with pulmonary embolism (PE) at intermediate-high risk for 30-day mortality. Material and methods. This single-center retrospective study included patients with confirmed intermediate-high-risk PE with thrombosis of the main or lobar branches of the pulmonary artery, no more than 14 days old. The patients were admitted to the cardiology intensive care units of the Almazov National Medical Research Center between January and December 2025. In accordance with the applied treatment strategy, patients were divided into 2 following groups: the UACDT group using EkoSonic technology (EKOS Corporation, Bothell, Washington, USA) and the ACT group. After 48 hours, the effectiveness of the treatment was assessed as follows: the incidence of decompensated hemodynamics episodes, the changes of right ventricle to left ventricle basal diameter ratio (RV/LV), decrease in the Qanadli score and the increase in residual peripheral flow according to computed tomography pulmonary angiography (CTPA), as well as the changes of right ventricular function echocardiographic parameters. Safety criteria included the incidence of minor and major bleeding. A telephone survey of patients was conducted one month after discharge to assess long-term outcomes. Results. The study included 41 patients, which were divided into 2 groups: ACT group — 21 patients; UACDT group — 20 patients. The endovascular treatment group showed a more pronounced reduction in right heart overload: Δ RV/LV according to CTPA was 0,40 [0,20; 0,70] in the UACDT group vs 0,03 [0,00; 0,40] in the ACT group (p=0,012). A reduction in the RV/LV ratio of more than 20% from baseline was achieved in 74% of cases in the UACDT group vs 30% of cases in the ACT group (p=0,010). According to echocardiography, there was a decrease in the right ventricular diameter by 11,0 [6,7; 13,8] mm in the UACDT group vs 6,0 [1,5; 8,5] mm in the ACT group (p=0,015), a decrease in the right atrial area by 5,20 [0,67; 6,25] cm 2 in the UACDT group vs 0,0 [-1,0; 2,8] cm 2 in the ACT group (p=0,050), a reduction in the inferior vena cava diameter by 2,0 [1,0; 6,0] mm in the UACDT group vs 0,0 [-0,5; 2,0] in the ACT group (p=0,040). In 2 cases (10%) in the UACDT group and in 6 cases (29%) in the conservative ACT group, hemodynamic destabilization was recorded (p=0,238), which served as the basis for "rescue" systemic thrombolytic therapy. Hemorrhagic events occurred in 5 cases (25,0%) in the UACDT group and in 2 cases (9,5%) in the ACT group (p=0,538). The incidence of minor and major bleeding was comparable between the groups as follows: 4 minor bleeding events in the UACDT group vs 2 in the ACT group (p=0,992) and 1 major bleeding event in the UACDT group vs 0 in the ACT group (p>0,999). Fatal outcomes were recorded in 1 case (5%) in the UACDT group and in 3 cases (14%) in the ACT group (p=0,606). Conclusion . There is a higher efficacy of UACDT in the form of a reduction in right ventricular overload in patients with intermediate-high-risk PE when compared with standard ACT with a comparable safety profile.

21 September 2022 in Innovative Medicine of Kuban
Verified
Journal Article
Open access
PDF file
MSM. A. Salov
M. A. Salov
ASA. S. Shulyakovskaya
A. S. Shulyakovskaya
IDI. N. Danilov
I. N. Danilov
TGT. D. Glebovskaya
T. D. Glebovskaya
KLK. B. Lapshin
K. B. Lapshin
ANA. E. Neymark
A. E. Neymark
Amiodarone is a drug used in the treatment of life-threatening arrhythmias, which can lead to the development of amiodarone-induced thyrotoxicosis. In most cases this pathology can be treated by conservative methods; surgical treatment is resorted to in cases of thyrotoxicosis refractory to medical treatment. This case report describes surgical treatment of a patient with amiodarone-induced thyrotoxicosis, progressive heart failure, neurological pathology, bilateral pneumonia, functioning tracheostomy, systemic infectious process, multiple organ dysfunction syndrome, who was treated in the intensive care unit. Due to the lack of response to therapy with antithyroid drugs (thiamazole, lithium preparations and pulse therapy with prednisolone) and a progressive deterioration of the condition in a short period of time, according to vital indicators, the patient underwent thyroidectomy. In the postoperative period, there was a decrease in the occurrence of chronic heart failure symptoms. Medical control of cardiac arrhythmias was achieved. Surgical stage proceeded without complications in the period of 30-days. The patient was discharged for outpatient rehabilitation treatment.